-
Product Insights
NewLikelihood of Approval Analysis for Leber Congenital Amaurosis (LCA)
Overview How likely is it that the drugs in Leber Congenital Amaurosis (LCA) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Leber Congenital Amaurosis (LCA) Overview Leber congenital amaurosis (LCA) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NFS-02 in Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NFS-02 in Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NFS-02 in Leber's Hereditary Optic Neuropathy...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ATSN-101 in Leber Congenital Amaurosis (LCA)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ATSN-101 in Leber Congenital Amaurosis (LCA) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ATSN-101 in Leber Congenital Amaurosis (LCA) Drug Details: ATSN-101 is...
-
Product Insights
Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) – Drugs In Development, 2023
Global Markets Direct’s, ‘Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) - Drugs In Development, 2023’, provides an overview of the Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete...
-
Product Insights
Leber Congenital Amaurosis (LCA) – Drugs In Development, 2023
Global Markets Direct’s, ‘Leber Congenital Amaurosis (LCA) - Drugs In Development, 2023’, provides an overview of the Leber Congenital Amaurosis (LCA) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Leber Congenital Amaurosis (LCA), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lenadogene Nolparvovec in Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lenadogene Nolparvovec in Leber's Hereditary Optic Neuropathy (Leber Optic Atrophy) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lenadogene Nolparvovec in Leber's Hereditary Optic...
-
Sector Analysis
NewCell and Gene Therapies in Ophthalmology – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies in Ophthalmology Market Report Overview The Cell and Gene Therapies (CGT) in ophthalmology market was $46 million in 2023. The market will experience moderate growth during the forecast period with gene therapies targeting Leber congenital amaurosis (LCA) and retinitis likely to be the primary drivers of the CGT market in the ophthalmology space. The CGT in ophthalmology market research report will aid clients in gaining insight into the competitive landscape of leading CGT agents in ophthalmology...
-
Product Insights
NewLikelihood of Approval Analysis for Retinal Degeneration
Overview How likely is it that the drugs in Retinal Degeneration will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Retinal Degeneration Overview Retinal degeneration refers to a group of diseases that...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LX-101 in Retinal Degeneration
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LX-101 in Retinal Degeneration report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LX-101 in Retinal Degeneration Drug Details: LX-101 is under investigation for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NFS-02 in Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.NFS-02 in Leber’s Hereditary Optic Neuropathy (Leber Optic Atrophy) Drug Details: NFS-02 is under development for...